By Cecilia Butini

 

Sanofi SA said Monday that its infant respiratory-virus drug Nirsevimab met its primary endpoint in a Phase 3 trial.

The French pharmaceutical company said the drug, which was being investigated as a single-dose immunization against respiratory syncytial virus, provided statistically significant reductions in lower respiratory tract infections in infants.

The drug has been developed in partnership with AstraZeneca PLC. Regulatory submissions are expected to begin in 2022, Sanofi said.

 

Write to Cecilia Butini at cecilia.butini@wsj.com

 

(END) Dow Jones Newswires

April 26, 2021 02:28 ET (06:28 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Historical Stock Chart
From Jun 2021 to Jul 2021 Click Here for more Sanofi Charts.
Sanofi (EU:SAN)
Historical Stock Chart
From Jul 2020 to Jul 2021 Click Here for more Sanofi Charts.